JamesMForanMD

PubMed

• Evaluation of Novel Targets, Including CC-Chemokine Receptor 4, in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma: A Mayo Clinic Clinical and Pathologic Study.
  Sharad Khurana, Michael G Heckman, Fiona E Craig, Jordan J Cochuyt, Patricia Greipp, Zaid Abdel Rahman, Lisa Z Sproat, Mark Litzow, Liuyan Jennifer Jiang, James M Foran> ;Archives of Pathology & Laboratory Medicine. 2024 Apr 1
• Efficacy of autologous and allogeneic hematopoietic cell transplantation in adults with acute promyelocytic leukemia: results of a systematic review and meta-analysis.
  Tea Reljic, Christian Kettaneh, Dua Al-Husni, Katelyn Keller, Ambuj Kumar, Razan Mohty, Farah Yassine, Talha Badar, Hemant Murthy, James Foran, Mohamed A Kharfan-Dabaja> ;Transplantation and Cellular Therapy. 2024 Mar 28
• Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
  Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Torghabeh, Mark R Litzow, Wi...> ;Haematologica. 2024 Mar 28
• Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
  Rizzieri, D., Pemmaraju, N., Madanat, Y., Fazal, S., Rampal, R., Mannis, G., Wang, E., Foran, J., Lane, A., Fazal, S.> ;Leukemia & Lymphoma. 2024 Feb 23
• Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms.
  Anmol Baranwal, Rong He, Hemant S Murthy, Mehrdad Hefazi, Aref Al-Kali, Hassan B Alkhateeb, Rami Basmaci, David Viswanatha, Patricia Greipp, James Foran, Jeanne Palmer...> ;Blood Advances. 2024 Feb 13
• Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.
  Anmol Baranwal, Mark Gurney, Rami Basmaci, Bahga Katamesh, Rong He, David S Viswanatha, Patricia Greipp, James Foran, Talha Badar, Hemant Murthy, Cecilia Arana Yi, Jea...> ;Haematologica. 2024 Feb 1
• 2 citations
  A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
  Cai, S., Huang, Y., Lance, J., Mao, H., Dunbar, A., McNulty, S., Druley, T., Li, Y., Baer, M., Stock, W., Kovacsovics, T., Blum, W., Schiller, G., Olin, R., Foran, J.,...> ;Blood Advances. 2024 Jan 23
• Loneliness, immunological recovery patterns, and health-related quality of life (HRQOL) outcomes in patients receiving hematopoietic stem cell transplantation.
  Lange, L., Ames, S., Ames, G., Heckman, M., White, L., Roy, V., Foran, J.> ;BMC Psychology. 2024 Jan 19
• A prospective study of the relationship between illness perception, depression, anxiety, and quality of life in hematopoietic stem cell transplant patients.
  Steven C Ames, Lori Lange, Gretchen E Ames, Michael G Heckman, Launia J White, Vivek Roy, James M Foran> ;Cancer Medicine. 2024 Feb 1
• 3 citations
  Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxi...
  Omer Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek Mang...> ;American Journal of Hematology. 2024 Feb 1
• 10 citations
  Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive...
  Naseema Gangat, Omer Karrar, Moazah Iftikhar, Kristen McCullough, Isla M Johnson, Maymona Abdelmagid, Mostafa Abdallah, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begn...> ;American Journal of Hematology. 2024 Feb 1
• 2 citations
  Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
  Farhad Ravandi, Asad Bashey, James Foran, Wendy Stock, Raya Mawad, Nicholas Short, Musa Yilmaz, Hagop Kantarjian, Olatoyosi Odenike, Anand Patel, Raman Garcha, William...> ;Blood Advances. 2023 Nov 14
• Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.
  Edward J Gorak, Michael Otterstatter, Tareq Al Baghdadi, Nancy Gillis, James M Foran, Jane Jijun Liu, Rafael Bejar, Steven D Gore, Steven H Kroft, Alexandra Harrington...> ;Blood Advances. 2023 Oct 24
• Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
  Uma Borate, Fei Yang, Richard Press, Amy S Ruppert, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Dean C Pavlick, Luke Juckett, Brianna Norris, Taylor Bu...> ;Blood Advances. 2023 Oct 24
• U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
  Talha Badar, Yenny A Moreno Vanegas, Ahmad Nanaa, James M Foran, Aref Al-Kali, Abhishek Mangaonkar, Hemant Murthy, Hassan B Alkhateeb, David Viswanatha, Rong He, Mithu...> ;Blood Cancer Journal. 2023 Sep 21
• 4 citations
  Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
  Ahmad Nanaa, Rong He, James M Foran, Talha Badar, Naseema Gangat, Animesh Pardanani, William J Hogan, Mark R Litzow, Mrinal Patnaik, Aref Al-Kali, Hassan B Alkhateeb> ;British Journal of Haematology. 2024 Jan 1
• 3 citations
  Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants.
  Alejandro Ferrer, Terra Lasho, Jenna A Fernandez, Nickolas P Steinauer, Rachel A Simon, Christy M Finke, Eva M Carmona, Mark E Wylam, Laura J Ongie, Brittany N Burnap,...> ;American Journal of Hematology. 2023 Dec 1
• 1 citations
  Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arte...
  Maymona G Abdelmagid, Aref Al-Kali, Mark R Litzow, Kebede H Begna, William J Hogan, Mirinal S Patnaik, Shahrukh K Hashmi, Michelle A Elliott, Hassan Alkhateeb, Omer S ...> ;Blood Cancer Journal. 2023 Aug 11
• IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience.
  Naseema Gangat, Helen Ajufo, Maymona Abdelmagid, Omer Karrar, Kristen McCullough, Talha Badar, James Foran, Jeanne Palmer, Hassan Alkhateeb, Abhishek Mangaonkar, Andre...> ;British Journal of Haematology. 2023 Nov 1
• Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia.
  Naseema Gangat, Kristen McCullough, Maymona Abdelmagid, Omer Karrar, Marissa Powell, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek Mangaonkar, Antoine Saliba,...> ;Haematologica. 2024 Jan 1
• 3 citations
  Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.
  Gregory A Abel, Donnie Hebert, Cecilia Lee, Dana Rollison, Nancy Gillis, Rami Komrokji, James M Foran, Jane Jijun Liu, Tareq Al Baghdadi, Joachim Deeg, Steven Gore, Wa...> ;Blood Advances. 2023 Jul 25
• 3 citations
  Clinical and molecular correlates of somatic and germlinevariants in patients and families with myeloid neoplasms.
  Talha Badar, Ahmad Nanaa, James M Foran, David Viswanatha, Aref Al-Kali, Terra Lasho, Christy Finke, Hassan B Alkhateeb, Rong He, Naseema Gangat, Mithun Shah, Ayalew T...> ;Haematologica. 2023 Nov 1
• 1 citations
  Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.
  James M Foran, Zhuoxin Sun, Catherine Lai, Hugo F Fernandez, Larry D Cripe, Rhett P Ketterling, Janis Racevskis, Selina M Luger, Elisabeth Paietta, Hillard M Lazarus, ...> ;Cancer. 2023 Aug 15
• 1 citations
  Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
  Vu H Duong, Amy S Ruppert, Alice S Mims, Uma Borate, Eytan M Stein, Maria R Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L Arellano, Gary J Schiller, Reb...> ;Cancer. 2023 Aug 1
• 2 citations
  Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome.
  Aref Al-Kali, Ahmad Nanaa, David Viswanatha, Rong He, Phuong Nguyen, Dragan Jevremovic, James M Foran, Cecelia Arana Yi, Patricia T Greipp, Naseema Gangat, Mrinal Patn...> ;Blood Cancer Journal. 2023 Apr 10
• Join now to see all

Journal Articles

• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine

Abstracts/Posters

• Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (A...
  James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
  James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
  James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
  James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
  James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
  James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Ly...
  James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
  James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Friday Scientific Workshop on Integrative Epidemiology: Translating Epidemiology and Basic Science to Maximize Clinical Impact 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Integrative Epidemiology: Translating Epidemiology and Basic Science to Maximize Clinical Impact 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Integrative Epidemiology: Translating Epidemiology and Basic Science to Maximize Clinical Impact 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Join now to see all